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Background: Heterotrimeric guanine nucleotide binding proteins of the G12/13 subfamily, which includes the
α-subunits Gα12 and Gα13, stimulate the monomeric G protein RhoA through interaction with a distinct subset of
Rho-specific guanine nucleotide exchange factors (RhoGEFs). The structural features that mediate interaction
between Gα13 and RhoGEFs have been examined in crystallographic studies of the purified complex, whereas a
Gα12:RhoGEF complex has not been reported. Several signaling responses and effector interactions appear unique
to Gα12 or Gα13, despite their similarity in amino acid sequence.
Methods: To comprehensively examine Gα12 for regions involved in RhoGEF interaction, we screened a panel of
Gα12 cassette substitution mutants for binding to leukemia-associated RhoGEF (LARG) and for activation of serum
response element mediated transcription.
Results: We identified several cassette substitutions that disrupt Gα12 binding to LARG and the related p115RhoGEF.
These Gα12 mutants also were impaired in activating serum response element mediated signaling, a Rho-dependent
response. Most of these mutants matched corresponding regions of Gα13 reported to contact p115RhoGEF, but
unexpectedly, several RhoGEF-uncoupling mutations were found within the N- and C-terminal regions of Gα12. Trypsin
protection assays revealed several mutants in these regions as retaining conformational activation. In addition, charge
substitutions near the Gα12 N-terminus selectively disrupted binding to LARG but not p115RhoGEF.
Conclusions: Several structural aspects of the Gα12:RhoGEF interface differ from the reported Gα13:RhoGEF complex,
particularly determinants within the C-terminal α5 helix and structurally uncharacterized N-terminus of Gα12.
Furthermore, key residues at the Gα12 N-terminus may confer selectivity for LARG as a downstream effector.
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The G12/13 subfamily of heterotrimeric guanine nucleo-
tide binding proteins (G proteins) is comprised of two α-
subunits in mammals, Gα12 and Gα13, that have been im-
plicated in a variety of physiological and pathological cel-
lular responses that include proliferation, cytoskeletal
rearrangements, migration, and metastatic invasion [1,2].
A diverse set of putative effector proteins have been iden-
tified as direct interactors with one or both G12/13 sub-
family members; however, the roles of individual Gα-
effector interactions in specific cellular responses remain
largely undefined [3]. The most extensively characterized* Correspondence: tmeigs@unca.edu
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reproduction in any medium, provided the orG12/13 target proteins are a subset of Rho-specific guan-
ine nucleotide exchange factors (RhoGEFs) that activate
the monomeric G protein Rho via tandem Dbl-homology
/pleckstrin-homology domains [4]. The Rho monomeric
GTPases are known primarily for their role in regulating
actin cytoskeletal dynamics, but these proteins also medi-
ate cell polarity, microtubule dynamics, membrane trans-
port pathways, transcription factor activity, cell growth,
and tumorigenesis [5]. The G12/13-RhoGEF-Rho axis me-
diates critical signaling and developmental pathways in
model organisms that include Drosophila melanogaster
[6], Caenorhabditis elegans [7], and zebrafish [8]. In
addition, direct interaction with RhoGEFs is required for
mutationally activated Gα12 to trigger increased invasive-
ness of breast cancer cells [9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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binding and stimulation of three distinct RhoGEFs:
p115RhoGEF, LARG and PDZ-RhoGEF [10-13]. This
interaction is mediated primarily by a domain, located
near the N-terminus of each RhoGEF, that is closely
related to the regulator of G protein signaling (RGS)
domain that defines the growing family of RGS proteins
[14,15]. Although p115RhoGEF, LARG and PDZ-
RhoGEF are highly similar in this “RGS homology“ (RH)
domain [16], these proteins appear to be activated by diffe-
rent mechanisms and play non-redundant roles in G12/13
subfamily-mediated signaling. Purified p115RhoGEF
binds Gα12 and Gα13 and accelerates GTPase activity for
both proteins, but only Gα13 can stimulate p115RhoGEF
to activate RhoA in vitro [10,17]. Interaction of Gα12 or
Gα13 with purified LARG can trigger its activation of
RhoA; however, stimulation by Gα12 requires prior phos-
phorylation of LARG by the nonreceptor tyrosine kinase
Tec [13]. Furthermore, studies utilizing small interfering
RNA to hinder expression of specific RhoGEFs show that
LARG is a specific downstream effector of thrombin
receptor-mediated signaling, whereas signaling through
the lysophosphatidic acid (LPA) receptor is attenuated by
blocking PDZ-RhoGEF expression [18]. These results are
compelling in light of a separate report that the thrombin
receptor shows preferential coupling to Gα12, whereas the
LPA receptor preferentially utilizes Gα13 as a conduit to
downstream signaling [19]. Although it is possible that
Gα12 stimulates a post-translationally modified form of
p115RhoGEF or PDZ-RhoGEF in cells, the evidence to
date suggests LARG as the most likely RhoGEF serving
as a physiological effector for Gα12. Gains in our under-
standing of the specificity of RhoGEF engagement
within the G12/13 subfamily should provide insights
into the non-overlapping functions of Gα12 and Gα13 in
signal transduction.
Crystallographic studies have revealed important struc-
tural aspects of the interaction between Gα13 and the RH
domain of p115RhoGEF, including numerous residues in
both proteins that provide contact points [20,21]. Initially,
purification of Gα13 for crystallography required that it be
engineered as a chimera in which amino acid sequence
within several regions, including the N- and C-termini,
was replaced by corresponding sequence from the Gi sub-
family protein Gαi1 [20]. The structure of the Gα13:
p115RhoGEF-RH complex was later refined in crystallo-
graphic studies that utilized a Gα13 chimera harboring
Gαi1 sequence only at the N-terminus. Because the Gα
N-terminus was unstructured in this crystallized complex,
any role of this region in RhoGEF interaction remains to
be determined. Although the region of Gα13 downstream
of the Switch III region harbors several residues critical for
RhoGEF engagement, notably Glu273, Thr274, Asn278, and
Arg279 within the α3 helix and α3-β5 loop, other regionscloser to the Gα13 C-terminus do not emerge in the crystal
structure as providing key RhoGEF contact points [21].
In contrast to Gα13, a structure of Gα12 in complex
with a RhoGEF target has not been reported, although a
chimeric Gα12 harboring the N-terminus of Gαi1 has
been crystallized [22]. To examine the full sequence of
Gα12 for structural features mediating its interaction
with RhoGEFs, we engineered a series of cassette substi-
tutions within constitutively activated Gα12 and exam-
ined these variants for in vitro binding to the RH
domains of LARG and p115RhoGEF, as well as ability to
drive the Rho-dependent process of serum response
element (SRE) mediated transcription in cells [23]. Our
results reveal unexpected regions of Gα12 as harboring
determinants of its functional interaction with RhoGEFs,
and also identify key charged amino acids near the Gα12
N-terminus that may confer selective binding to LARG.
Results
Myc-tagged Gα12 retains RhoGEF binding, Rho-mediated
signaling, and conformational activation
To identify mutants of Gα12 impaired in RhoGEF binding,
we first sought to establish an in vitro system in which
Gα12 mutants could be expressed ectopically in cultured
cells, rendered soluble in a detergent extract, and detected
without interference from endogenous Gα12. We
engineered the constitutively active Gln229Leu variant of
Gα12 (Gα12
QL) to harbor a myc epitope tag, flanked by
linkers of the sequence SGGGGS and positioned between
residues Pro139 and Val140. This insertion site was chosen
due to its approximate alignment with the position of
green fluorescent protein in Gαq in a prior study [24]. We
expressed myc-tagged and untagged Gα12
QL in HEK293
cells, prepared detergent-soluble extracts, and analyzed
these by immunoblotting. As shown in Figure 1A, myc-
tagged Gα12
QL was detected by both anti-myc and anti-Gα
12 antibodies, with the latter generating a much stronger
signal while avoiding an off-target 37 kDa band detected
in all samples by the anti-myc antibody. Also, the myc-
tagged protein (~45 kDa) was readily discernible from en-
dogenous Gα12 and untagged Gα12
QL (~43 kDa). Next, we
subjected myc-Gα12
QL to pulldown experiments using an
immobilized GST fusion of the p115RhoGEF RH domain,
as described in Methods. Myc-tagged and untagged
Gα12
QL bound to p115-RH with similar affinity
(Figure 1B), and comparison with mock-transfected
cells indicated the ~45 kDa band detected by anti-Gα12
was dependent on transfection with the myc-Gα12
QL
plasmid. Furthermore, LARG-RH and p115-RH showed
similar ability to co-precipitate myc-tagged Gα12
QL
(Figure 1C). To ascertain that myc-Gα12 is functional as a
mediator of cellular signal transduction through Rho, we
measured transcriptional activation of a luciferase reporter
gene positioned downstream of the serum response
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Figure 1 Effector binding and conformational activation of myc-tagged, constitutively activated Gα12. Molecular weight markers (in kDa)
are indicated at right of panels where applicable. All results shown are representative of two or more independent experiments. (A) Expression
and solubilization of Gα12QL (12QL) and myc-tagged Gα12QL (myc-12QL) transiently expressed in HEK293 cells. Cells transfected with the vector
pcDNA3.1 are included as a negative control (vector). Detergent-soluble extracts were prepared by high-speed centrifugation and subjected to
SDS-PAGE and immunoblotting, using either anti-myc (Zymed) or anti-Gα12 (Santa Cruz Biotechnology) antibodies as described in Methods. (B) In
vitro binding of myc-tagged and untagged Gα12QL by p115RhoGEF. HEK293 cells extracts containing myc-Gα12QL were subjected to protein
interaction assays (see Methods) using an immobilized GST fusion of the RH domain of p115RhoGEF (RGS) or GST alone (GST). Samples were
washed, separated by SDS-PAGE, and analyzed by immunoblotting using antibodies described above. (C) Specificity of myc-Gα12QL detection in
interaction assays. HEK293 cells transfected with either myc-Gα12QL (myc-12QL) or the empty pcDNA3.1 plasmid (vect) were lysed and assayed for
binding to GST fusions of the RH domain of p115RhoGEF (p115) or LARG, or GST alone (GST). Immunoblot analysis was performed using anti-Gα12
antibody as described above. (D) Serum response element (SRE) luciferase activation by myc-Gα12QL. HEK293 cells grown in 12-well plates were
co-transfected with the plasmids SRE-L (0.2 μg) and pRL-TK (0.02 μg), plus 0.1 μg of the plasmid indicated on the X-axis. Y-axis values show firefly
luciferase signal normalized for Renilla luciferase signal within each sample. (E) Trypsin protection assays of myc-tagged Gα12. Lysates from
HEK293 cells transfected with myc-Gα12QL (myc-12QL) or the constitutively GDP-bound Gly228Ala mutant of wildtype Gα12 (myc-12G228A) were
subjected to trypsin digests as described in Methods. Immunoblot analysis was performed using J169 antibody [25] at 1:700 dilution.
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provides a readout of Gα12-mediated Rho activation [23].
Myc-tagged and untagged Gα12
QL exhibited similar ability
to stimulate this response in HEK293 cells co-transfected
with SRE-luciferase (Figure 1D). Furthermore, trypsin di-
gestion of HEK293 cell lysates harboring myc-Gα12
QL
yielded a protected fragment of ~40 kDa, comparable to
results observed previously with GTPγS-loaded, purified
Gα12 [25]. An inactive, constitutively GDP-bound
(Gly228Ala) variant of myc-tagged Gα12 did not yield
this ~40 kDa fragment when digested with trypsin
(Figure 1E). Taken together, these results suggest myc-Gα12
QL undergoes conformational activation and retains
normal signaling through the RhoGEF:Rho pathway. Be-
cause of the superior sensitivity of anti-Gα12 antibody in
detecting myc-Gα12
QL, and the easily discernible gel shift
of Gα12 caused by the myc tag and linkers (see Figures 1A
and B), we chose to utilize anti-Gα12 to detect myc-Gα
12
QL in subsequent protein binding experiments.
Mutations that uncouple Gα12 from RhoGEF binding and
Rho-mediated signaling
To scan Gα12 for regions participating in its interaction
with RhoGEFs, we utilized a comprehensive panel of
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myc-Gα12
QL are replaced by the sextet Asn-Ala-Ala-Ile-
Arg-Ser (Figure 2 shows the native amino acid sextet
and alphabetical designation for each mutant). This
strategy of “NAAIRS” cassette substitutions was chosen
due to prediction of this motif being tolerated in the
three-dimensional structure of proteins [26], prior use of
this approach in mapping functional regions of both
retinoblastoma and the telomerase catalytic subunit
[27,28], and our previous success employing this strategy
to identify Gα12 determinants of binding to the scaffold-
ing subunit of protein phosphatase-2A and the cytoplas-
mic tail of polycystin-1 [29,30]. Variants of Gα12 were
expressed in HEK293 cells and tested for interaction
with immobilized LARG-RH, as described in Methods.
As shown in Figure 3, myc-Gα12
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Figure 2 Residues replaced in Gα12 cassette mutants. For each mutant
sextet replaced by the sequence Asn-Ala-Ala-Ile-Arg-Ser is shown. An arrow
Mutant W was not produced. The dashed box indicates the native Gln229 m
replaced in mutant KKK are Lys-Asp-Ile-Met-Leu-Gln and thus partially overl
mutation, except mutant LL due to its cassette substitution.by a GST fusion of LARG-RH but not by GST alone.
Many of these cassette mutants yielded a moderate-to
-robust signal in the LARG-precipitated fraction; how-
ever, a subset displayed a weak or absent signal
(Figure 3). To assess impairment of LARG binding for
each myc-Gα12
QL variant, we quantified the band inten-
sity for each precipitated sample (pulldown), and divided
this by the band intensity in the starting cellular extract
(load). These calculations generated a “pulldown:load ra-
tio” for each mutant, and also for the positive control
myc-Gα12
QL that was tested in each experiment. Nearly
all cassette mutants were solubilized by our detergent
conditions and detected by immunoblotting; exceptions
were mutant W, which we did not engineer due to over-
lap with the insertion site of the myc tag (see Figure 2),
and mutant CC due to low expression levels thatA G A R E R R A G A A
I D A L L A R E R R A
E S G K S T F L K Q M
M S GN-term.
L E F R D T I F D N I
L G I P W Q H S E N E
G L P V E P A T F Q L
I R E A F S R R S E F
D R I G Q L N Y F P S
I V E H D F V I K K I
R Q K W F Q C F D G I
Q V L M E D R R T N R
N K L F F N V S I I L
S V S I K K H F P D F
L V Q C F D R K R R N
I D T E N I R F V F H A
I M L Q C-term.
C D
G H
AA BB
CCC
K L
O P
S T
W X
EE FF
II JJ
MM NN
QQ RR
UU VV
YY ZZ
DDD
GGG HHH
KKK
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between Pro139 and Val140 indicates the site of myc tag insertion.
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Figure 3 In vitro interaction of Gα12 mutants with LARG. Immunoblot results for all LARG binding-impaired Gα12 cassette mutants and selected
other mutants are shown. HEK293 cells were transfected with the indicated plasmids (7.0 μg per 10-cm plate) and lysates were prepared for co-
precipitation assays as described in Methods. Prior to this step, 5% of each lysate was set aside as starting material (load). Pulldown experiments were
performed on 7–9 mutants per experiment, plus myc-Gα12QL as a positive control, using equal amounts of GST-LARG-RH (LARG) immobilized on
glutathione-sepharose. Immobilized GST was utilized in parallel as a negative control. For all experimental samples, 20% of the volume was analyzed
by SDS-PAGE and Coomassie blue staining to verify equal amounts of GST-LARG-RH and GST proteins in the precipitates (data not shown).
Immunoblots displayed in this figure are representative of at least three trials per cassette mutant, except for mutants A-D, F-H, V, and KKK that showed
minimal impairment in LARG binding after two trials. (Inset) Coomassie blue analysis of GST-fusion constructs expressed in bacteria and immobilized
on glutathione-sepharose: GST-LARG-RH (LARG), GST-p115-RH (p115), and GST alone. Molecular weight standards (in kDa) are indicated at right.
Table 1 Gα12 cassette mutants impaired in binding LARG-RH
70-100% A-D F-H L N O T-V X BB DD-FF II KK XX YY BBB DDD III-KKK
40-70% H P GG JJ WW ZZ CCC
20-40% Y AA PP
10-20% I OO QQ-SS UU VV FFF
0-10% E J K M Q R S Z HH LL-NN TT AAA EEE GGG HHH
N/D W CC
Cassette substitution mutants of myc-Gα12
QL (see Figure 2 for alphabetical
designations) were expressed in HEK293 cells and subjected to protein interaction
assays using a GST-fusion of the RH domain of LARG as described in Methods, and
for each mutant a pulldown:load ratio was determined and calculated as a
percent (left column) of the same ratio for unmodified myc-Gα12
QL assayed in
parallel. Each Gα12 mutant was analyzed in three independent experiments,
except for mutants that appeared in the 70-100% category in two
independent experiments.
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in Table 1, the majority of cassette mutants exhibited
pulldown:load ratios greater than 40% of the ratio deter-
mined for myc-Gα12
QL. However, a number of mutants
exhibited lower pulldown:load ratios (<20% of positive
control) with a subset generating a ratio less than 10% of
the positive control. For all samples, precipitation by
immobilized GST yielded no Gα12 signal (Figure 3), indi-
cating these mutants were not merely binding the GST-
glutathione-sepharose complex nor forming insoluble
aggregates under these in vitro conditions. Also, we exam-
ined the full panel of Gα12 cassette mutants for interaction
with a GST fusion of the N-terminal 252 amino acids of
p115RhoGEF (p115-RH). None of the LARG binding-
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positive control; see Table 1) yielded a signal intensity in the
p115-RH precipitate that exceeded 50% of intensity for the
positive control myc-Gα12
QL (data not shown).
The Gα12 cassette mutant designated OO was among
those impaired in LARG binding, consistent with our
previous work demonstrating its uncoupling from Rho-
mediated signaling [31], and several other cassette sub-
stitutions within the Switch regions disrupted binding to
LARG (mutants HH, LL, MM, NN, QQ, and RR; see
Figure 2). However, impaired LARG binding also was
caused by substitutions in other regions of Gα12
(Table 1). Prior crystallographic studies identified se-
veral residues in Gα13 that serve as contact points with
p115-RH [20,21]. Table 2 lists Gα13 residues identified as
contact points with p115-RH in these earlier studies, and
indicates the corresponding Gα12 cassette mutant for
each Gα13 residue. From our in vitro binding results
(Table 1), it is apparent that most Gα12 mutants corre-
sponding to RhoGEF-contacting Gα13 residues displayed
partial or severe impairment of LARG binding, mutants V,
BB and DDD being exceptions. However, several RhoGEF-
uncoupling substitutions in Gα12 (cassette mutants E, I, J,
K, M, Z, NN, OO, VV, AAA, EEE, FFF, GGG and HHH)
replaced amino acids that do not correspond to Gα13 con-
tacts with p115-RH. Gα12 mutants J and K replaced sec-
tions of the P-loop, a motif critical in guanine nucleotide
binding, and thus would be predicted as impaired in
signaling. However, our finding of RhoGEF-uncouplingTable 2 Gα12 cassette mutants corresponding to rgRGS
contact points within Gα13
Gα13 residues in contact
with p115-RH
myc-Gα12
QL NAAIRS
mutant
Val98 Q
Asp101, Ala102 R
Lys105, Leu106 S
Thr127, Arg128 V
Phe168 BB
Arg200, Pro202, Lys204 HH
Gln226 LL
Arg230, Lys231, Phe234 MM
Met257 QQ
Arg260 RR
Asn270 SS
Ile271, Glu273, Thr274, Ile275 TT
Asn278, Arg279, Val280 UU
Arg335 DDD
Gα13-native residues previously identified as providing contact points with the
RH domain of p115RhoGEF [20,21] are indicated in the left column. Cassette
mutants (“NAAIRS” substitution) in which the homologous residue(s) within
Gα12 have been altered are indicated in the right column. See Figure 2 for
Gα12 mutant designations.mutations at the N- and C-termini of Gα12 was unex-
pected, because these regions either lacked corresponding
contact points in the Gα13:p115-RH complex or were disor-
dered in the G12/13 crystal structures (i.e. the N-terminus).
To determine whether these N- and C-terminal mutations
in Gα12 are impaired in Rho-mediated signaling, we
expressed these variants in HEK293 cells and measured
stimulation of SRE-luciferase transcription. All N- and
C-terminal mutants impaired in RhoGEF binding were
poor activators of this reporter gene (Figure 4A). Several
cassette mutants in the N- and C-terminal regions of
Gα12 that displayed normal binding to LARG (mutants
F, V, and KKK) stimulated SRE-luciferase in a manner
comparable to the myc-Gα12
QL positive control (Figure 4A).
With the exception of mutant VV, immunoblot analysis of
HEK293 cell lysates revealed expression levels of these mu-
tants similar to myc-Gα12
QL (Figure 4B).
Conformational activation of RhoGEF-uncoupled Gα12
mutants
A concern in our experimental approach was that
specific “NAAIRS” cassette substitutions could cause
global disruption of Gα12 shape, so that a mutant might
fail to assume an activated conformation. For RhoGEF-
uncoupled Gα12 mutants at the N-terminus (i.e. upstream
of the P-loop) and C-terminus, we measured protection
against trypsin proteolysis. Exchange of GDP for the acti-
vating GTP on Gα proteins triggers a conformational
change that conceals a trypsin cleavage site within the
Switch II region; this property allows the activated state of
the Gα protein to be revealed by resistance to trypsin
[25,32]. As shown in Figure 5A, mutants E, I, and HHH
yielded a protected fragment of approximately 40 kDa that
matched the fragment observed following tryptic digestion
of myc-Gα12
QL. Results for mutant AAA were difficult to
interpret; a band of slightly smaller size than undigested
AAA was generated by tryptic digestion, but it was unclear
whether this matched the ~40 kDa trypsin-protected
fragment in myc-Gα12
QL. Other C-terminal mutants
we tested− VV, EEE, FFF, and GGG− appeared to
match the constitutively inactive myc-Gα12
G228A
which lacked this ~40 kDa fragment (Figure 5A). These
results suggest several C-terminal mutants of Gα12 were
sufficiently distorted in shape by the “NAAIRS” substitu-
tion to allow trypsin access to proteolytic sites normally
not exposed in the GTP-bound state. However, cassette
mutants E and I at the N-terminus and HHH at
the C-terminus appeared to maintain an activated
conformation despite their impairment in RhoGEF
binding and SRE stimulation.
We also tested whether RhoGEF-uncoupled cassette
mutants at the N- and C-termini of Gα12 could interact
in vitro with other reported binding partners: heat shock
protein-90, protein phosphatase-5, the scaffolding Aα
Figure 4 Activation of serum response element mediated transcription by Gα12 mutants. (A) Luciferase reporter assay results of selected
cassette mutants. HEK293 cells grown in 12-well plates were co-transfected with the plasmids SRE-L (0.2 μg) and pRL-TK (0.02 μg), plus 1.0 μg of
the plasmid encoding each cassette mutant indicated on the X-axis. Firefly luciferase values were normalized for Renilla luciferase values within
each sample, and values are presented as a percent of the value calculated for myc-Gα12QL (Y-axis) within the same experiment. Mutationally
active (12QL) and inactive (G228A) samples were analyzed in parallel. Results shown are a representative of two experiments performed per Gα12
variant. (B) Expression level of Gα12 mutants. A sample of each lysate was set aside prior to luminometry and analyzed by SDS-PAGE and
immunoblotting using anti-Gα12 antibody (Santa Cruz Biotechnology). For all samples, densitometric intensity was determined as described in
Methods, then divided by positive control myc-Gα12
QL levels within the same experiment, and SRE-L/Renilla values were adjusted to reflect this
normalization for protein levels.
12QL 12G228A E I VV AAA
12QL EEE
tryp:
A
FFF GGG HHH
B E I VV AAA EEE FFF GGG HHH
LARG
Hsp90
PP5
PP2A
E-cad
Figure 5 Conformational efficacy of N-terminal and C-terminal Gα12 mutants uncoupled from RhoGEFs. (A) Trypsin protection of selected
Gα12 mutants. HEK293 cell lysates expressing the indicated variants of myc-Gα12
QL, or unmodified myc-Gα12
QL (12QL), or the G228A variant of myc-
Gα12 (12G228A) were subjected to trypsin protection assays as described in Methods. Samples were incubated 20 min at 30°C in the presence (+)
or absence (−) of TPCK-treated trypsin, and were analyzed by SDS-PAGE and immunoblotting using J169 antibody (1:700 dilution). Small
horizontal arrows indicate position of the trypsin-protected fragment in selected lanes. Data presented are representative of two or more
independent experiments per sample. (B) Specificity of uncoupling in selected Gα12 variants. For each cassette mutant of myc-Gα12QL (indicated
at top), interaction with each Gα12 target (indicated at left) was quantified as a pulldown:load ratio as described in Methods, and was calculated
as a percent of the identical ratio determined for myc-Gα12QL within the same experiment. Values are indicated as follows: (++) = >60%, (+) = 20
to 60%, (−) = 0 to 20%. Interacting proteins are GST fusions of the following: RH domain of LARG (LARG), C-terminal 107 amino acids of heat
shock protein-90 alpha (Hsp90), protein phosphatase-5 (PP5), scaffolding Aα subunit of protein phosphatase-2A (PP2A), C-terminal 98 amino acids
of E-cadherin (E-cad). Values presented indicate the mean of two or more trials per interaction sample.
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http://www.jmolecularsignaling.com/content/8/1/3subunit of protein phosphatase-2A, and the cytoplasmic
tail of E-cadherin [33-36]. As shown in Figure 5B, each
mutant displayed pulldown:load ratios >60% of the positive
control, myc-Gα12
QL, for at least two of these non-
RhoGEF targets. Taken as a whole, these findings reveal a
subset of mutations at the N- and C-terminus that select-
ively uncouple Gα12 from RhoGEFs while preserving con-
formational activation and ability to bind other
downstream proteins.
We next visualized the position of these RhoGEF-
interacting regions in the crystal structure of a Gα12
chimera in which the N-terminal 48 residues were re-
placed by the N-terminus of Gαi1 [22]. The native
region of Gα12 replaced in cassette mutant E is not or-
dered in this structure; however, the regions replaced
in the C-terminal mutants EEE-HHH are highlighted
(Figure 6). The sextet replaced in mutant HHH
(highlighted in black) resides in the α5 helix that extends
along the Gα12 surface and approaches the C-terminus at
the top of the diagram.
Differential uncoupling of Gα12 from LARG and
p115RhoGEF
We next sought to identify specific residues within these
N- and C-terminal sextets of Gα12 that mediate RhoGEF
interaction. To examine putative surface residues, we
performed charge substitutions in the native regionsFigure 6 Structural position of Gα12 C-terminal determinants of
RhoGEF binding. The structure of N-terminally Gαi1-substituted
Gα12 (PDB accession code 1ZCA, [22]) as a GDP•AlF4¯ activated
complex was analyzed using PyMOL software. The native Gα12
region substituted for the sequence “NAAIRS” in the C-terminal
mutants EEE, FFF, and GGG is highlighted in orange, and the sextet
substituted in mutant HHH is highlighted in black. The bound GDP
molecule is highlighted in blue. Figure was rendered in The PyMOL
Molecular Graphics System, Version 1.5.0.1 Schrödinger, LLC.corresponding to cassette mutants E, I, and HHH, and
examined these variants for SRE-luciferase activation.
None of the single-residue charge-reversals in the
regions encompassed in mutants I or HHH caused
significant decrease in SRE signaling (data not shown).
However, a double charge-reversal in the mutant E
region, converting Glu31 and Glu33 to Arg residues, caused
a near-complete loss of SRE activation in HEK293 cells des-
pite normal levels of protein expression (Figure 7A). We
next examined this Gα12 mutant, designated Glu
31/33Arg,
for binding to the RH domains of LARG and p115RhoGEF.
As shown in Figure 7B, a selective loss of RhoGEF binding
was observed: the Glu31/33Arg charge-reversals severely
disrupted LARG-RH binding relative to non-mutated
myc-Gα12
QL (pulldown:load ratio ~18% of control) but
had minimal effect on p115-RH binding (ratio ~86% of
control). In trypsin protection assays, the Glu31/33Arg
mutant yielded a protected fragment at the same mo-
lecular weight (~40 kDa) as observed for the myc-Gα
12
QL positive control, suggesting its ability to attain an
activated conformation (Figure 7C). The intermediate
intensity of this band (approximately a midpoint
between activated Gα12 and the constitutively inactive
Gly228Ala variant) may be due in part to the mutational
introduction of Arg residues providing additional sites
for trypsin proteolysis. Taken as a whole, these findings
not only provide evidence that the structurally
uncharacterized N-terminus of Gα12 plays a role in its
functional interaction with RhoGEFs, but also reveal in-
dividual charged residues in this region as candidates
for conferring specificity of Gα12 for LARG among the
RH-containing RhoGEFs.
Discussion
The G12 subfamily members Gα12 and Gα13 are well-
documented as utilizing RhoGEFs as downstream signal-
ing effectors. Crystallographic studies by Chen et al. [20]
and Hajicek et al. [21] have provided intricate structural
details of the interaction between Gα13 and the RH
domain of p115RhoGEF, identifying a set of Gα13 resi-
dues that directly contact this target protein. The struc-
ture of Gα12 also has been elucidated, using a chimera
comprised of amino acids 49–379 of Gα12 preceded by
amino acids 1–28 of Gαi1 [22]. However, a Gα12:RhoGEF
complex has not been reported. In the current study, we
utilized in vitro and cell-based approaches to examine
the interaction between Gα12 and two putative target
RhoGEFs, LARG and p115RhoGEF. Using immobilized
RGS-homology (RH) domains of these RhoGEFs, we
identified several substitutions of native amino acids in
Gα12 that disrupted its binding to these proteins and
blocked its ability to stimulate the Rho-dependent
process of SRE-mediated transcription. Although our re-
sults indicated that a number of common determinants
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Figure 7 Selective RhoGEF uncoupling by N-terminal charge
substitutions in Gα12. (A) Luciferase reporter gene assays. Cassette
mutant E (see Figure 2) and the double charge substitution mutant
Glu31/33Arg were compared to myc-Gα12
QL (12QL) in SRE-luciferase
assays under the cell transfection conditions described in Figure 4. A
constitutively GDP-bound variant of wildtype myc-Gα12 (12G228A) was
assayed in parallel as a negative control. Results shown are the
mean of three independent experiments, and error bars indicate
range. (B) Protein-protein interaction assays. Detergent-soluble
extracts from transfected HEK293 cells transfected with myc-Gα12QL,
the Glu31/33Arg mutant, or empty pcDNA3.1 plasmid (vector) were
subjected to co-precipitation assays as described in Methods, using
GST-fusions of either LARG-RH (LARG), p115RhoGEF-RH (p115), the
N-terminal domain of the Gα12 target radixin [46], or no adduct
(GST). Prior to the precipitation step, 5% of each lysate was set aside
as starting material (load). Table values show the pulldown:load ratio
for Glu31/33Arg as a percent of the positive control value (12QL), with
mean +/- range presented for three independent experiments.
(C) Trypsin protection of the Glu31/33Arg mutant, in comparison to
constitutively GTP- and GDP-bound Gα12. Assays were performed as
described in Methods. Results shown are representative of two
independent experiments.
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RhoGEF-uncoupling mutations in Gα12 did not corres-
pond to regions of RhoGEF contact within Gα13; these in-
clude amino acid sextet substitutions in the C-terminal α5
helix as well as the structurally uncharacterized N-terminus
. Several of these Gα12 mutants exhibited protection from
tryptic digestion as well as unimpeded binding to other,
non-RhoGEF targets, indicating their impaired interaction
with RhoGEFs is not caused by failure to attain an activated
conformation and suggesting the shapes of other effector-
binding surfaces in these Gα12 mutants remain intact as
RhoGEF interaction is disrupted.
Although Gα12 and Gα13 share 67% amino acid
identity and bind several common downstream targets,
several functional differences between these Gα proteins
suggest their signaling mechanisms are not redundant
[1,3]. Both Gα12 and Gα13 bind LARG and p115RhoGEF
[10,12], and both of these RhoGEFs accelerate GTPase
activity of purified Gα12 and Gα13 in single-turnover
assays [13,17]. Whereas Gα13 stimulates both p115RhoGEF
and LARG to trigger guanine nucleotide exchange on
RhoA in vitro, Gα12 can only stimulate LARG under these
experimental conditions, and in a manner dependent on
prior phosphorylation of LARG by the tyrosine kinase Tec
[10,13]. Also, activated Gα12 is more potent than Gα13 in
recruiting the RH domain of p115RhoGEF to the plasma
membrane, and specific mutations in p115RhoGEF disrupt
Gα12 but not Gα13 in triggering this localization [37]. At
the cellular and organismal levels, it is increasingly
clear that Gα12 and Gα13 utilize non-overlapping sig-
naling pathways. Mice lacking Gα13 die early in em-
bryogenesis due to defects in vascular development and
thrombin-induced cell migration, but mice lacking
Gα12 do not display these developmental defects. How-
ever, knockout of Gα12 combined with absence of Gα13
causes earlier lethality than Gα13 knockout alone, and
in mice lacking one Gα13 allele, at least one Gα12 allele
must be present for normal embryonic development
[38,39]. Furthermore, LPA-induced activation of mTOR
complex 2 leading to activation of PKC-δ requires Gα12
but not Gα13 [40]. Because of these differences, plus
the increasing list of Gα12-specific effector proteins
(including another RhoGEF, AKAP-Lbc, that is acti-
vated exclusively by Gα12 within the G12/13 subfamily),
we believe the Gα12:RhoGEF interface cannot be defined
summarily by structural features of the Gα13:RhoGEF
complex.
Among the Gα13 residues that provide contact points
with p115RhoGEF in crystallographic studies [20,21],
many have corresponding residues within Gα12, and
therefore we paid particular attention to Gα12 cassette
mutants corresponding to these key Gα13 residues (see
Table 2). For example, the Gα12 mutant HH replaced
residues corresponding to Gα13 residues Arg
200, and
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p115-RH. In another Gα12 cassette mutant, termed RR, a
substituted residue corresponds to Arg260 within Gα13;
this residue provides a key contact with amino acids
within the βN-αN region of p115RhoGEF. Also, Gα12
cassette mutants Q, R, and S contain altered residues in
the Gα12 helical domain that correspond to p115-RH
interacting residues in Gα13. Among the Gα12 mutants
corresponding to p115-RH contact points in Gα13, most
showed impaired RhoGEF interaction and poor stimula-
tion of SRE-mediated signaling. However, several differ-
ences between Gα12 and Gα13 were noted, particularly in
the helical domain. Gα12 cassette mutant V alters resi-
dues that correspond to two contact points within the
Gα13:p115-RH complex; however, this mutant showed
minimal impairment in RhoGEF binding in vitro and
stimulated SRE-mediated transcription robustly in cells.
Gα12 mutant BB, which removes a Phe corresponding to
a Gα13 contact point with p115-RH, displayed a slight
impairment in SRE-mediated transcriptional activation
and no impairment of RhoGEF binding. In addition,
Gα13 utilizes a C-terminal residue (Arg
335) as a contact
point with p115-RH, but the corresponding Gα12 cassette
mutant (DDD) exhibited normal binding to RhoGEFs
and only modest impairment in SRE signaling. However,
because this cassette mutant preserves the corresponding
Arg residue in Gα12 (DRKRRN substituted for NAAIRS),
it is possible this Arg in Gα12 participates in RhoGEF
binding despite the alteration in adjacent amino acids.
Aside from the N- and C-terminal mutants of Gα12
that show impaired RhoGEF binding, we have identified
other RhoGEF-uncoupling mutations in Gα12 that lack
corresponding Gα13 contact points for p115-RH (see
Tables 1 and 2). None of the native Gα12 residues
replaced in cassette mutants M and Z match p115-RH
contact points in Gα13, and thus may indicate Gα12-spe-
cific determinants of RhoGEF interaction. Impaired
RhoGEF binding also was observed in Gα12 mutants J
and K; however, this most likely was due to these sub-
stitutions disrupting the canonical GXGXXGKS guan-
ine nucleotide binding motif [41]. Although our
results suggest a core similarity in the mechanisms
utilized by Gα12 and Gα13 to engage RhoGEF targets,
it is apparent that several determinants of RhoGEF
binding are unique to Gα13. We have identified deter-
minants that may be unique to Gα12 or potentially
important for both G12/13 subfamily members in
RhoGEF engagement. Studies of Gα13 variants harbor-
ing corresponding mutations will be important in
distinguishing these possibilities.
A role for the C-terminus of G12/13 subfamily pro-
teins in RhoGEF engagement has been suggested by
prior studies. Kreutz et al. [42] engineered chimeras of
Gα12 and Gα13 that were interchanged downstream ofthe Switch III region, and demonstrated the C-terminal
114 amino acids of Gα13 as sufficient for its unique abil-
ity to stimulate purified p115RhoGEF to activate RhoA.
Also, a chimeric Gα13 in which the region downstream
of Switch III was replaced by the corresponding re-
gion of Gαi2 displayed loss of ability to stimulate
SRE-mediated transcriptional activation [43]. Initial
crystallographic studies of Gα13:RhoGEF interaction
utilized a chimeric Gα13 harboring Gαi1 sequence at
the C-terminus, and determinants of RhoGEF binding
were not found downstream of the Switch regions in this
protein [20]. Subsequent crystallographic work utilizing
Gα13 with native C-terminal sequence did identify resi-
dues slightly downstream of the Switch III region as
critical for RhoGEF engagement [21], and also revealed a
more distal residue in the C-terminal region (Arg335) as pro-
viding a contact point with the RH domain of p115RhoGEF.
However, no residues at the extreme C-terminus of
Gα13, including the α5 helix, were found to mediate
RhoGEF binding. Our results suggest differences be-
tween Gα12 and Gα13 in the role of the C-terminus, as
several substitutions near the extreme C-terminus of Gα12
disrupted RhoGEF interaction, most notably the cassette
mutant HHH within the α5 helix.
The N-terminus provides the greatest amino acid
sequence divergence between Gα12 and Gα13. Gα sub-
units utilize this region for interaction with Gβγ [44],
and in Gα12 and Gα13 this region confers specificity of
coupling to thrombin and LPA receptors, respectively
[19]. Importantly, Gα13 is a more potent stimulator of
RhoGEF activation in vitro than a chimeric Gα13 harbor-
ing the N-terminus of Gαi1, indicating a possible role of
the Gα13 N-terminus in RhoGEF activation [21]. How-
ever, specific determinants within the N-terminus of
G12/13 subfamily proteins that mediate binding to effec-
tors, including RhoGEFs, have not been reported. The
48-residue region at the N-terminus of Gα12 has not
been characterized in crystallographic studies, because
its replacement by the Gαi1 N-terminus was necessary
for obtaining sufficient quantities of purified protein
[16,22]. Furthermore, the N-terminus was disordered in
crystallographic analysis of both the aforementioned
Gαi1/Gα13 hybrid and a more recent structure of full-
length Gα13 [21], suggesting the Gα12 N-terminus may
be refractory to crystallographic analysis even if native
sequence is utilized. Our approach of employing cassette
substitution mutants throughout the length of Gα12 has
provided an indirect means of circumventing this obs-
tacle, and has revealed specific N-terminal regions as
possible determinants of RhoGEF interaction. Import-
antly, our discovery that mutations in this N-terminal
region (cassette mutants E and I) cause loss of RhoGEF
binding allowed us to focus on putative surface residues
in these substituted regions, ultimately revealing Glu31
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and stimulation of SRE-mediated transcription. Our
finding that charge substitutions of these N-terminal
Gα12 residues disrupted binding to the LARG-RH do-
main but had minimal effect on interaction with the cor-
responding domain of p115RhoGEF was intriguing, and
suggested these residues play a role in targeting Gα12
preferentially to LARG. It is possible that Gα12 harbors
sufficient RhoGEF-interacting surfaces for in vitro bind-
ing to p115RhoGEF, but that a functional, physiological
interaction (i.e. with LARG) requires this N-terminal re-
gion. Our RhoGEF binding results for Gα12 cassette mu-
tant E, as well as the more specific Glu31/33Arg mutant,
were surprising in light of earlier findings that RhoGEF
binding was preserved in a Gα12 chimera containing the
Gαi1 N-terminus [22]. It is possible that “NAAIRS”
substitution and particularly the Glu31/33Arg charge-
reversals cause a more dramatic change to this RhoGEF
binding surface than occurs when Gαi1 sequence is intro-
duced. Cassette mutant E and the Glu31/33Arg mutant
are impaired in activating the Rho-dependent readout of
SRE-mediated transcriptional activation in cells, and
it remains to be determined whether the Gαi1/Gα12
chimera is similarly impaired in stimulating this pathway.
Because previous phosphorylation of LARG by Tec is
a requirement for Gα12, but not Gα13, for in vitro activa-
tion of Rho, it will be important to determine whether this
phosphorylation event regulates interaction of LARG with
Gα12, particularly its N-terminus and C-terminal α5 helix.
Furthermore, as suggested by Hajicek et al. [21], it is
conceivable that post-translational modification of
p115RhoGEF in cells modulates its responsiveness to
Gα13 or could potentially render it a target of Gα12. A
challenge for future studies of Gα12- and Gα13-mediated
signaling will be to determine the combinations of G12/
13 subfamily α-subunits and RhoGEFs that activate Rho
in response to different signaling inputs, and in different
cell and tissue types.
Conclusions
Gα12 and Gα13 define the G12/13 class of heterotrimeric
G protein α-subunits, which participate in numerous
signaling pathways through stimulation of RhoGEFs that
subsequently activate Rho. Although these proteins are
non-redundant in their stimulation of effectors and their
cellular and organismal roles, only Gα13 has been char-
acterized in the structural basis of its interaction with
RhoGEF targets. However, the involvement of Gα12 in
stimulating SRE-mediated transcription, cell rounding,
c-Jun N-terminal kinase activation, cell growth, and
metastatic invasion supports a physiological role for a
Gα12-RhoGEF-Rho axis in developmental pathways and
disease progression [45]. Therefore, an improved under-
standing of the structural aspects of Gα12:RhoGEFinteraction likely will be of broad importance. Our re-
sults provide several key additions to this structural
model: 1) characterization of the Gα12:RhoGEF interacting
surface by identifying regions in Gα12 that mediate
binding; 2) unexpected roles of the Gα12 N-terminal
region and C-terminal α5 helix in engagement of
RhoGEFs; 3) identification of specific residues near the
Gα12 N-terminus that may mediate its selectivity for
LARG as an effector protein. To date, no structural
studies have examined the interaction of Gα12 with
RhoGEFs. Our hope is that mutant-based strategies will
augment such crystallographic approaches and provide
key details toward understanding the structural aspects
and biological role of this Gα:effector interaction.
Methods
DNA constructs
Plasmids encoding 1) a fusion of glutathione-S-transferase
(GST) to amino acids 320–606 of LARG (GST-LARG-
RH), and 2) amino acids 1–252 of p115RhoGEF with an
N-terminal myc epitope tag were kindly provided by
Tohru Kozasa (Univ. of Ill., Chicago). We used PCR to
subclone the p115RhoGEF sequence into pGEX-2T (GE
Healthcare) to produce GST-p115-RH. All “NAAIRS”
amino acid substitution mutants within myc-tagged Gα12
Gln229Leu (myc-Gα12
QL) were engineered as described
previously [29]. Single amino acid substitutions were
engineered in myc-Gα12
QL using the QuikChange IIW site-
directed mutagenesis system (Agilent Technologies), and
this system was used to engineer a constitutively inactive
Gly228Ala variant (myc-Gα12
G228A) within a plasmid en-
coding myc-tagged, wildtype Gα12 (provided by Pat Casey,
Duke University). The luciferase reporter plasmid SRE-L
was a gift from Channing Der (University of North
Carolina Chapel Hill).
Expression and immobilization of GST fusion proteins
GST fusion constructs were transformed into BL21
(Gold)-DE3 cells (Stratagene). Cells were grown under
75 μg/ml ampicillin selection to OD600 of 0.5−0.7, and re-
combinant protein expression was induced using 0.5 mM
isopropyl-β-D-thiogalactopyranoside (Fisher Scientific).
After 3 h, cells were lysed on ice using 0.32 mg/ml lyso-
zyme (MP Biomedicals), and GST fusion proteins were
bound to glutathione-sepharose 4B (GE Healthcare) as de-
scribed previously [31,34]. Following three washes in
50 mM Tris pH 7.7 supplemented with 1 mM EDTA,
1 mM dithiothreitol, and 150 mM NaCl, samples were
snap-frozen in aliquots and stored at −80°C.
Preparation of detergent-soluble extracts harboring Gα12
mutants
Human embryonic kidney cells (HEK293) were grown in
Dulbecco’s modified Eagle medium (Mediatech, Manassas,
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Logan, UT), penicillin and streptomycin. For myc-Gα12
QL
and each of its 62 NAAIRS substitution mutants (see
Figure 2), 7.0 μg of plasmid DNA was transfected into a
10-cm dish of HEK293 cells grown to approximate 90%
confluence, using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. After 36–
42 hours, cells were scraped from dishes, washed twice
with phosphate-buffered saline, and solubilized in
NAAIRS Lysis buffer (50 mM HEPES pH 7.5, 1 mM
EDTA, 3 mM dithiothreitol, 10 mM MgSO4, 1% (w/v)
polyoxyethylene-10-lauryl ether) containing the prote-
ase inhibitors 4-(2-aminoethyl)benzenesulfonyl fluoride
hydrochloride (1.67 mM), leupeptin (2.1 μM), pepstatin
(1.45 μM), TLCK (58 μM), TPCK (61 μM), and
phenylmethylsulfonyl fluoride (267 μM). Samples were
centrifuged at 80,000 g for 1 h, and supernatants were
snap-frozen in 60-μl aliquots and stored at −80°C.Protein interaction assays
HEK293 cell extracts were diluted in NAAIRS Lysis buf-
fer lacking polyoxyethylene-10-lauryl ether, using suffi-
cient volume to dilute this detergent in the samples to
0.05% (w/v). Next, sepharose-bound GST fusion pro-
teins were added and allowed to incubate for approxi-
mately 2 h at 4°C with continuous inversion. A
percentage of the diluted extract was set aside as
starting material prior to sepharose addition. Next,
samples were centrifuged at 1,300 g, and pellets were
washed three times and then subjected to SDS-PAGE
and immunoblot analysis using an antibody specific to
the Gα12 N-terminus (Santa Cruz Biotechnology) or the
myc 9E10 epitope tag (Zymed), followed by alkaline
phosphatase conjugated secondary antibodies (Promega).
For each variant of myc-Gα12
QL, the Gaussian intensity
of the ~45 kDa band from the precipitated material and
the corresponding band from the starting material were
quantified using a Kodak Gel Logic 100 system equipped
with Molecular Imaging 5.X software (Carestream
Health, New Haven CT).Reporter gene assays
HEK293 cells grown in 12-well plates were transfected
with 0.2 μg SRE-luciferase plasmid (encoding firefly lu-
ciferase) and 0.02 μg pRL-TK plasmid encoding Renilla
luciferase, plus plasmids encoding variants of myc-Gα
12
QL. Reporter assays for SRE-mediated transcriptional
activation were performed as described previously [31].
Briefly, cells were washed with phosphate-buffered sa-
line and lysed in 1X passive lysis buffer (Promega), and
lysates were analyzed using a Dual-luciferase assay sys-
tem and GloMax 20/20 luminometer (Promega). Light
output due to firefly luciferase activity was divided byoutput from Renilla luciferase activity to normalize
samples for transfection efficiency.
Trypsin protection experiments
HEK293 cells grown in 10-cm dishes were transfected
with various Gα12 constructs using Lipofectamine 2000
(Invitrogen), and tryptic digestions were performed as a
modification of the procedure of Kozasa and Gilman
[25]. Briefly, cells were lysed in 50 mM Hepes pH 8.0,
1 mM EDTA, 3 mM dithiothreitol, 1% polyoxyethylene-
10-lauryl ether containing the same protease inhibitors
as NAAIRS Lysis buffer (see above) but at two-fold
lower concentration. Samples were cleared by centrifu-
gation at 70,000 g for 1 h, and supernatants were diluted
20-fold in volume using 50 mM Hepes pH 8.0, 1 mM
EDTA, 3 mM dithiothreitol, 10 mM MgSO4. Samples
were digested with 10 μg/ml TPCK-treated trypsin (New
England Biolabs) for 20 min at 30°C, and proteolysis was
terminated by addition of 100 μg/ml lima bean trypsin
inhibitor (Worthington, Lakewood NJ). Samples were
analyzed by SDS-PAGE and immunoblotting using J169
antisera specific to the Gα12 C-terminus, provided by
Tohru Kozasa (Univ. of Ill., Chicago).
Abbreviations
Gα12 and Gα13: Heterotrimeric guanine nucleotide binding protein
α-subunits of the G12/13 subfamily; GST: Glutathione-S-transferase;
HEK: Human embryonic kidney; LARG: Leukemia-associated RhoGEF;
LPA: Lysophosphatidic acid; NAAIRS mutant: Variant of Gα12 in which a
consecutive sextet of native residues has been replaced by Asn-Ala-Ala-Ile-
Arg-Ser; RGS: Regulator of G protein signaling; RH: RGS homology;
RhoGEF: Rho-specific guanine nucleotide exchange factor; SRE: Serum
response element.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BJR and WCS participated in design of the study, carried out PCR-based
mutagenesis, designed and executed protein interaction screens, and
participated in drafting the manuscript. In addition, BJR performed reporter
assays and WCS performed 3-D protein imaging and analysis. ERM, ESF, TYC,
and CMO engineered various GST-fusion constructs and carried out protein
interaction screens. LAF participated in initial design of the study and carried
out pilot experiments. TEM conceived of the study, participated in its design,
coordination, engineering of constructs and data collection, and drafted the
manuscript. All authors have read and approved the final manuscript.
Authors’ information
TEM is an affiliate member of the UNC Lineberger Comprehensive Cancer
Center (Chapel Hill, NC).
Acknowledgements
We are grateful to Tohru Kozasa, Channing Der, and Pat Casey for reagents,
and Todd DeMarco, Benjamin Smith, and Joseph Martin for technical
assistance. We thank Pat Casey for critical reading of this manuscript, and
Dan Kaplan, Juhi Juneja, Pat Kelly, Tim Fields, and Nicole Hajicek for helpful
discussions. TEM, WCS, and ERM received support from the Lineberger
Comprehensive Cancer Center (Chapel Hill, NC) through a University Cancer
Research Fund collaborative award. BJR, ERM, ESF, CMO, and TEM were
supported by a grant from the North Carolina Biotechnology Center (BRG-
1229). LAF received support from the UNC-Asheville Undergraduate Research
Program. TEM received additional support as co-investigator on National
Institutes of Health grant CA100869.
Ritchie et al. Journal of Molecular Signaling 2013, 8:3 Page 13 of 14
http://www.jmolecularsignaling.com/content/8/1/3Received: 23 January 2013 Accepted: 17 March 2013
Published: 25 March 2013References
1. Worzfeld T, Wettschureck N, Offermanns S: G12/G13-mediated signalling in
mammalian physiology and disease. Trends Pharmacol Sci 2008,
29:582–589.
2. Suzuki N, Hajicek N, Kozasa T: Regulation and physiological functions of
G12/13-mediated signaling pathways. Neurosignals 2009, 17:55–70.
3. Kelly P, Casey PJ, Meigs TE: Biologic functions of the G12 subfamily of
heterotrimeric G proteins: growth, migration, and metastasis.
Biochemistry 2007, 46:6677–6687.
4. Sternweis PC, Carter AM, Chen Z, Danesh SM, Hsiung YF, Singer WD:
Regulation of Rho guanine nucleotide exchange factors by G proteins.
Adv Protein Chem 2007, 74:189–228.
5. Jaffe AB, Hall A: Rho GTPases: biochemistry and biology. Annu Rev Cell Dev
Biol 2005, 21:247–269.
6. Barrett K, Leptin M, Settleman J: The Rho GTPase and a putative RhoGEF
mediate a signaling pathway for the cell shape changes in Drosophila
gastrulation. Cell 1997, 91:905–915.
7. Yau DM, Yokoyama N, Goshima Y, Siddiqui ZK, Siddiqui SS, Kozasa T:
Identification and molecular characterization of the Gα12-Rho guanine
nucleotide exchange factor pathway in Caenorhabditis elegans. Proc Natl
Acad Sci USA 2003, 100:14748–14753.
8. Lin F, Sepich DS, Chen S, Topczewski J, Yin C, Solnica-Krezel L, Hamm H:
Essential roles of Gα12/13 signaling in distinct cell behaviors driving
zebrafish convergence and extension gastrulation movements. J Cell Biol
2005, 169:777–787.
9. Kelly P, Moeller BJ, Juneja J, Booden MA, Der CJ, Daaka Y, Dewhirst MW,
Fields TA, Casey PJ: The G12 family of heterotrimeric G proteins promotes
breast cancer invasion and metastasis. Proc Natl Acad Sci USA 2006,
103:8173–8178.
10. Hart MJ, Jiang X, Kozasa T, Roscoe W, Singer WD, Gilman AG, Sternweis PC,
Bollag G: Direct stimulation of the guanine nucleotide exchange activity
of p115 RhoGEF by Gα13. Science 1998, 280:2112–2114.
11. Fukuhara S, Murga C, Zohar M, Igishi T, Gutkind JS: A novel PDZ domain
containing guanine nucleotide exchange factor links heterotrimeric G
proteins to Rho. J Biol Chem 1999, 274:5868–5879.
12. Fukuhara S, Chikumi H, Gutkind JS: Leukemia-associated Rho guanine
nucleotide exchange factor (LARG) links heterotrimeric G proteins of the
G(12) family to Rho. FEBS Lett 2000, 485:183–188.
13. Suzuki N, Nakamura S, Mano H, Kozasa T: Gα12 activates Rho GTPase
through tyrosine-phosphorylated leukemia-associated RhoGEF. Proc Natl
Acad Sci USA 2003, 100:733–738.
14. Hollinger S, Hepler JR: Cellular regulation of RGS proteins: modulators
and integrators of G protein signaling. Pharmacol Rev 2002, 54:527–559.
15. Siderovski DP, Willard FS: The GAPs, GEFs, and GDIs of heterotrimeric
G-protein alpha subunits. Int J Biol Sci 2005, 1:51–66.
16. Chen Z, Singer WD, Danesh SM, Sternweis PC, Sprang SR: Recognition of
the activated states of Gα13 by the rgRGS domain of PDZRhoGEF.
Structure 2008, 16:1532–1543.
17. Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, Bollag G,
Sternweis PC: p115 RhoGEF, a GTPase activating protein for Gα12 and
Gα13. Science 1998, 280:2109–2111.
18. Wang Q, Liu M, Kozasa T, Rothstein JD, Sternweis PC, Neubig RR: Thrombin
and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate
cancer cells. J Biol Chem 2004, 279:28831–28834.
19. Yamaguchi Y, Katoh H, Negishi M: N-terminal short sequences of α
subunits of the G12 family determine selective coupling to receptors.
J Biol Chem 2003, 278:14936–14939.
20. Chen Z, Singer WD, Sternweis PC, Sprang SR: Structure of the p115RhoGEF
rgRGS domain-Gα13/i1 chimera complex suggests convergent evolution
of a GTPase activator. Nat Struct Mol Biol 2005, 12:191–197.
21. Hajicek N, Kukimoto-Niino M, Mishima-Tsumagari C, Chow CR, Shirouzu M,
Terada T, Patel M, Yokoyama S, Kozasa T: Identification of critical residues
in Gα13 for stimulation of p115RhoGEF activity and the structure of the
Gα13-p115RhoGEF regulator of G protein signaling homology (RH)
domain complex. J Biol Chem 2011, 286:20625–20636.
22. Kreutz B, Yau DM, Nance MR, Tanabe S, Tesmer JJG, Kozasa T: A new
approach to producing functional Gα subunits yields the activated anddeactivated structures of Gα12/13 proteins. Biochemistry 2006,
45:167–174.
23. Fromm C, Coso OA, Montaner S, Xu N, Gutkind JS: The small GTP-binding
protein Rho links G protein-coupled receptors and Gα12 to the serum
response element and to cellular transformation. Proc Natl Acad Sci USA
1997, 94:10098–10103.
24. Hughes TE, Zhang H, Logothetis DE, Berlot CH: Visualization of a functional
Gαq-green fluorescent protein fusion in living cells. Association with the
plasma membrane is disrupted by mutational activation and by
elimination of palmitoylation sites, but not by activation mediated by
receptors or AlF4
–. J Biol Chem 2001, 276:4227–4235.
25. Kozasa T, Gilman AG: Purification of recombinant G proteins from Sf9
cells by hexahistidine tagging of associated subunits. Characterization of
α12 and inhibition of adenylyl cyclase by αz. J Biol Chem 1995,
270:1734–1741.
26. Wilson IA, Haft DH, Getzoff ED, Tainer JA, Lerner RA, Brenner S: Identical
short peptide sequences in unrelated proteins can have different
conformations: a testing ground for theories of immune recognition.
Proc Natl Acad Sci USA 1985, 82:5255–5259.
27. Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB,
Kaelin WG: Stable binding to E2F is not required for the retinoblastoma
protein to activate transcription, promote differentiation, and suppress
tumor cell growth. Genes Dev 1998, 12:95–106.
28. Armbruster BN, Banik SS, Guo C, Smith AC, Counter CM: N-terminal
domains of the human telomerase catalytic subunit required for enzyme
activity in vivo. Mol Cell Biol 2001, 21:7775–7786.
29. Zhu D, Tate RI, Ruediger R, Meigs TE, Denker BM: Domains necessary for Gα12
binding and stimulation of protein phosphatase-2A (PP2A): Is Gα12 a novel
regulatory subunit of PP2A? Mol Pharmacol 2007, 71:1268–1276.
30. Yu W, Ritchie BJ, Su X, Zhou J, Meigs TE, Denker BM: Identification of
polycystin-1 and Gα12 binding regions necessary for regulation of
apoptosis. Cell Signal 2011, 23:213–221.
31. Meigs TE, Juneja J, DeMarco CT, Stemmle LN, Kaplan DD, Casey PJ:
Selective uncoupling of Gα12 from Rho-mediated signaling. J Biol Chem
2005, 280:18049–18055.
32. Miller RT, Masters SB, Sullivan KA, Beiderman B, Bourne HR: A mutation that
prevents GTP-dependent activation of the α chain of Gs. Nature 1988,
334:712–715.
33. Vaiskunaite R, Kozasa T, Voyno-Yasenetskaya TA: Interaction between the
Gα subunit of heterotrimeric G12 protein and Hsp90 is required for Gα12
signaling. J Biol Chem 2001, 276:46088–46093.
34. Meigs TE, Fields TA, McKee DD, Casey PJ: Interaction of Gα12 and Gα13
with the cytoplasmic domain of cadherin provides a mechanism for β-
catenin release. Proc Natl Acad Sci USA 2001, 98:519–524.
35. Yamaguchi Y, Katoh H, Mori K, Negishi M: Gα12 and Gα13 interact with Ser/
Thr protein phosphatase type 5 and stimulate its phosphatase activity.
Curr Biol 2002, 12:1353–1358.
36. Zhu D, Kosik KS, Meigs TE, Yanamadala V, Denker BM: Gα12 directly
interacts with PP2A: evidence for Gα12-stimulated PP2A phosphatase
activity and dephosphorylation of microtubule-associated protein, Tau.
J Biol Chem 2004, 279:54983–54986.
37. Bhattacharyya R, Banerjee J, Khalili K, Wedegaertner PB: Differences in Gα12-
and Gα13-mediated plasma membrane recruitment of p115-RhoGEF.
Cell Signal 2009, 21:996–1006.
38. Offermanns S, Mancino V, Revel JP, Simon MI: Vascular system defects and
impaired cell chemokinesis as a result of Gα13 deficiency. Science 1997,
275:533–536.
39. Gu JL, Muller S, Mancino V, Offermanns S, Simon MI: Interaction of Gα12
with Gα13 and Gαq signaling pathways. Proc Natl Acad Sci USA 2002,
99:9352–9357.
40. Gan X, Wang J, Wang C, Sommer E, Kozasa T, Srinivasula S, Alessi D,
Offermanns S, Simon MI, Wu D: PRR5L degradation promotes mTORC2-
mediated PKC-δ phosphorylation and cell migration downstream of
Gα12. Nat Cell Biol 2012, 14:686–696.
41. Hamm HE, Gilchrist A: Heterotrimeric G proteins. Curr Opin Cell Biol 1996,
8:189–196.
42. Kreutz B, Hajicek N, Yau DM, Nakamura S, Kozasa T: Distinct regions of
Gα13 participate in its regulatory interactions with RGS homology
domain-containing RhoGEFs. Cell Signal 2007, 19:1681–1689.
43. Vazquez-Prado J, Miyazaki H, Castellone MD, Teramoto H, Gutkind JS:
Chimeric Gαi2/Gα13 proteins reveal the structural requirements for the
Ritchie et al. Journal of Molecular Signaling 2013, 8:3 Page 14 of 14
http://www.jmolecularsignaling.com/content/8/1/3binding and activation of the RGS-like (RGL)-containing Rho guanine
nucleotide exchange factors (GEFs) by Gα13. J Biol Chem 2004,
279:54283–54290.
44. Denker BM, Neer EJ, Schmidt CJ: Mutagenesis of the amino terminus of
the alpha subunit of the G protein Go. In vitro characterization of αoβγ
interactions. J Biol Chem 1992, 267:6272–6277.
45. Juneja J, Casey PJ: Role of G12 proteins in oncogenesis and metastasis.
Br J Pharmacol 2009, 158:32–40.
46. Vaiskunaite R, Adarichev V, Furthmayr H, Kozasa T, Gudkov A,
Voyno-Yasenetskaya TA: Conformational activation of radixin by G13
protein α subunit. J Biol Chem 2000, 275:26206–26212.
doi:10.1186/1750-2187-8-3
Cite this article as: Ritchie et al.: Determinants at the N- and C-termini of
Gα12 required for activation of Rho-mediated signaling. Journal of
Molecular Signaling 2013 8:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
